دورية أكاديمية
Prognostic gene expression signature for high-grade serous ovarian cancer.
| العنوان: | Prognostic gene expression signature for high-grade serous ovarian cancer. |
|---|---|
| المؤلفون: | Millstein J; Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA., Budden T; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; CRUK Manchester Institute, The University of Manchester, Manchester, UK., Goode EL; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, USA., Anglesio MS; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Talhouk A; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada., Intermaggio MP; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia., Leong HS; Peter MacCallum Cancer Center, Melbourne, Australia., Chen S; Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA., Elatre W; Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA., Gilks B; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada., Nazeran T; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Volchek M; Anatomical Pathology, Royal Women's Hospital, Parkville, Australia., Bentley RC; Department of Pathology, Duke University Hospital, Durham, USA., Wang C; Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA., Chiu DS; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Kommoss S; Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany., Leung SCY; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Senz J; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada., Lum A; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Chow V; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Sudderuddin H; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., Mackenzie R; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada., George J; The Jackson Laboratory for Genomic Medicine, Farmington, USA., Fereday S; Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Hendley J; Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Traficante N; Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Steed H; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Canada., Koziak JM; Alberta Health Services-Cancer Care, Calgary, Canada., Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Canada., McNeish IA; Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Goranova T; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Ennis D; Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Macintyre G; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Silva De Silva D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Ramón Y Cajal T; Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain., García-Donas J; HM Hospitales D Centro Integral Oncológico HM Clara Campal, Madrid, Spain., Hernando Polo S; Medical Oncology Service, Hospital Universitario Funcacion Alcorcon, Alcorcón, Spain., Rodriguez GC; Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, USA., Cushing-Haugen KL; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA., Harris HR; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA., Greene CS; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Zelaya RA; Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, USA., Behrens S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Fortner RT; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Sinn P; Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Herpel E; Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany., Lester J; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA., Lubiński J; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland., Oszurek O; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland., Tołoczko A; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland., Cybulski C; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland., Menkiszak J; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland., Pearce CL; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, USA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA., Pike MC; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA., Tseng C; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA., Alsop J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK., Rhenius V; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK., Song H; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK., Jimenez-Linan M; Department of Pathology, Addenbrooke's Hospital NHS Trust, Cambridge, UK., Piskorz AM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Gentry-Maharaj A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK., Karpinskyj C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK., Widschwendter M; Department of Women's Cancer, Institute for Women's Health, University College London, London, UK., Singh N; Department of Pathology, Barts Health National Health Service Trust, London, UK., Kennedy CJ; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Sharma R; Pathology West ICPMR Westmead, Westmead Hospital, The University of Sydney, Sydney, Australia; University of Western Sydney at Westmead Hospital, Sydney, Australia., Harnett PR; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia., Gao B; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia., Johnatty SE; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Sayer R; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Boros J; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Winham SJ; Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA., Keeney GL; Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA., Larson MC; Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA., Luk H; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA., Hernandez BY; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA., Thompson PJ; Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA., Wilkens LR; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA., Carney ME; John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, USA., Trabert B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA., Lissowska J; Department of Cancer Epidemiology and Prevention, M Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland., Brinton L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA., Sherman ME; Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, USA., Bodelon C; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA., Hinsley S; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Lewsley LA; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Glasspool R; Department of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK., Banerjee SN; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK., Stronach EA; Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK., Haluska P; Department of Oncology, Mayo Clinic, Rochester, USA., Ray-Coquard I; Centre Leon Berard and University Claude Bernard Lyon 1, Lyon, France., Mahner S; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany., Winterhoff B; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, USA., Slamon D; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA., Levine DA; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA; Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, USA., Kelemen LE; Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, USA., Benitez J; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Gronwald J; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland., Wu AH; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA., Menon U; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK., Goodman MT; Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA., Schildkraut JM; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA., Wentzensen N; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA., Brown R; Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK., Berchuck A; Department of Gynecologic Oncology, Duke University Hospital, Durham, USA., Chenevix-Trench G; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., deFazio A; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia., Gayther SA; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, USA., García MJ; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain., Henderson MJ; Children's Cancer Institute, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia., Rossing MA; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA., Beeghly-Fadiel A; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA., Fasching PA; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany., Orsulic S; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA., Karlan BY; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA., Konecny GE; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA., Huntsman DG; British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada., Bowtell DD; Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Doherty JA; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, USA., Pharoah PDP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK., Ramus SJ; School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia. Electronic address: s.ramus@unsw.edu.au. |
| مؤلفون مشاركون: | AOCS Group; Peter MacCallum Cancer Center, Melbourne, Australia; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia. |
| المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Sep; Vol. 31 (9), pp. 1240-1250. Date of Electronic Publication: 2020 May 28. |
| نوع المنشور: | Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
| مواضيع طبية MeSH: | Cystadenocarcinoma, Serous*/genetics , Ovarian Neoplasms*/genetics, Female ; Humans ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Transcriptome |
| مستخلص: | Background: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. Patients and Methods: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. Results: Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. Conclusion: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches. Competing Interests: Disclosure BYK served on Invitae Corporation's Advisory Board from 2017 to 2018. IAM has acted on the Advisory Boards for AstraZeneca, Clovis Oncology, Tesaro, Carrick Therapeutics and Takeda. His institution receives funding from AstraZeneca. RG is on the Advisory Boards for AstraZeneca, Tesaro, Clovis and Immunogen and does consultancy work for SOTIO. She has received support to attend conferences from AstraZeneca, Roche and Tesaro. Her institution has received research funding from Boehringer Ingelheim and Lilly/Ignyta and she is the national co-ordinating investigator for the UK for trials sponsored by AstraZeneca and Tesaro and site principal investigator for trials sponsored by AstraZeneca, Tesaro, Immunogen, Pfizer, Lilly and Clovis. PAF has received grants from Novartis, BioNtech and Cepheid as well as personal fees from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, Astra Zeneca, Merck Sharp & Dohme, Myelo Therapeutics, MacroGenics, Eisai and Puma during the conduct of the study. JDB has acted on Advisory Boards for AstraZeneca and has received support from GSK to attend conferences. His institution receives funding from AstraZeneca and Aprea. UM has shares in Abcodia Ltd. Sandra Orsulic and Beth Y. Karlan have patents on predictive gene signatures in ovarian cancer (US010253368 and EU2908913). All remaining authors have declared no conflicts of interest. (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| References: | Oncogene. 2018 Sep;37(37):5088-5100. (PMID: 29795405) Genome Biol. 2016 May 23;17(1):108. (PMID: 27215396) Cell. 2017 Aug 24;170(5):927-938.e20. (PMID: 28841418) CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280) Gene Ther. 2006 Sep;13(17):1263-71. (PMID: 16672984) EBioMedicine. 2019 May;43:9-10. (PMID: 30979685) Clin Cancer Res. 2015 Feb 1;21(3):652-7. (PMID: 25398451) PLoS One. 2016 Apr 20;11(4):e0153844. (PMID: 27096160) Cancer. 2009 Mar 15;115(6):1234-44. (PMID: 19189349) Clin Cancer Res. 2020 Jun 17;:. (PMID: 32554541) Cancer Res. 2014 Jun 1;74(11):3084-91. (PMID: 24728075) Gynecol Oncol. 2015 Oct;139(1):30-9. (PMID: 26232338) N Engl J Med. 2018 Dec 27;379(26):2495-2505. (PMID: 30345884) Gynecol Oncol. 2014 Feb;132(2):334-42. (PMID: 24368280) Int J Gynecol Cancer. 2018 Jan;28(1):51-58. (PMID: 28976449) J Natl Cancer Inst. 2014 Sep 30;106(10):. (PMID: 25269487) N Engl J Med. 2003 Jan 16;348(3):203-13. (PMID: 12529460) Nucleic Acids Res. 2002 Jan 1;30(1):207-10. (PMID: 11752295) Cancer Res. 2008 Jul 1;68(13):5478-86. (PMID: 18593951) J Immunol. 2007 Feb 15;178(4):2278-86. (PMID: 17277133) PLoS Comput Biol. 2013;9(3):e1002975. (PMID: 23555212) Nature. 2011 Jun 29;474(7353):609-15. (PMID: 21720365) JAMA. 2012 Jan 25;307(4):382-90. (PMID: 22274685) Front Genet. 2013 Sep 17;4:179. (PMID: 24062767) Nat Rev Cancer. 2015 Nov;15(11):668-79. (PMID: 26493647) Br J Cancer. 2016 Aug 23;115(5):553-63. (PMID: 27490802) Cancer Treat Rev. 2018 Feb;63:40-47. (PMID: 29207310) Nat Rev Cancer. 2011 Sep 23;11(10):719-25. (PMID: 21941283) JAMA Oncol. 2017 Dec 1;3(12):e173290. (PMID: 29049607) PLoS One. 2011;6(11):e24709. (PMID: 22073136) Lancet Oncol. 2017 Sep;18(9):1274-1284. (PMID: 28754483) Clin Cancer Res. 2008 Aug 15;14(16):5198-208. (PMID: 18698038) |
| معلومات مُعتمدة: | R01 CA172404 United States CA NCI NIH HHS; P30 CA034196 United States CA NCI NIH HHS; MC_UU_12023/20 United Kingdom MRC_ Medical Research Council; UL1 TR000124 United States TR NCATS NIH HHS; P30 CA014089 United States CA NCI NIH HHS; 15601 United Kingdom CRUK_ Cancer Research UK; R01 CA200854 United States CA NCI NIH HHS; 13086 United Kingdom CRUK_ Cancer Research UK; A16561 United Kingdom CRUK_ Cancer Research UK; P30 CA008748 United States CA NCI NIH HHS; K22 CA193860 United States CA NCI NIH HHS; 22905 United Kingdom CRUK_ Cancer Research UK; P01 CA196569 United States CA NCI NIH HHS; R01 CA168758 United States CA NCI NIH HHS; P50 CA136393 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Investigator: D Bowtell; G Chenevix-Trench; A Green; P Webb; A DeFazio; D Gertig; N Traficante; S Fereday; S Moore; J Hung; K Harrap; T Sadkowsky; N Pandeya; M Malt; A Mellon; R Robertson; T Vanden Bergh; M Jones; P Mackenzie; J Maidens; K Nattress; YE Chiew; A Stenlake; H Sullivan; B Alexander; P Ashover; S Brown; T Corrish; L Green; L Jackman; K Ferguson; K Martin; A Martyn; B Ranieri; J White; V Jayde; P Mamers; L Bowes; L Galletta; D Giles; J Hendley; K Alsop; T Schmidt; H Shirley; C Ball; C Young; S Viduka; H Tran; S Bilic; L Glavinas; J Brooks; R Stuart-Harris; F Kirsten; J Rutovitz; P Clingan; A Glasgow; A Proietto; S Braye; G Otton; J Shannon; T Bonaventura; J Stewart; S Begbie; M Friedlander; D Bell; S Baron-Hay; A Ferrier A; G Gard; D Nevell; N Pavlakis; S Valmadre; B Young; C Camaris; R Crouch; L Edwards; N Hacker; D Marsden; G Robertson; P Beale; J Beith; J Carter; C Dalrymple; R Houghton; P Russell; M Links; J Grygiel; J Hill; A Brand; K Byth; R Jaworski; P Harnett; R Sharma; G Wain; B Ward; D Papadimos; A Crandon; M Cummings; K Horwood; A Obermair; L Perrin; D Wyld; J Nicklin; M Davy; MK Oehler; C Hall; T Dodd; T Healy; K Pittman; D Henderson; J Miller; J Pierdes; P Blomfield; D Challis; R McIntosh; A Parker; B Brown; R Rome; D Allen; P Grant; S Hyde; R Laurie; M Robbie; D Healy; T Jobling; T Manolitsas; J McNealage; P Rogers; B Susil; E Sumithran; I Simpson; K Phillips; D Rischin; S Fox; D Johnson; S Lade; M Loughrey; N O'Callaghan; W Murray; P Waring; V Billson; J Pyman; D Neesham; M Quinn; C Underhill; R Bell; LF Ng; R Blum; V Ganju; I Hammond; Y Leung; A McCartney; M Buck; I Haviv; D Purdie; D Whiteman; N Zeps Keywords: formalin-fixed paraffin-embedded; gene expression; high-grade serous ovarian cancer; overall survival; prognosis |
| تواريخ الأحداث: | Date Created: 20200531 Date Completed: 20210106 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC7484370 |
| DOI: | 10.1016/j.annonc.2020.05.019 |
| PMID: | 32473302 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1569-8041 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.05.019 |